Cocrystal Pharma Inc. has showcased its latest advancements in antiviral drug development through a recent investor presentation. The company is focusing on high-value antiviral drug targets, including influenza, norovirus, and coronaviruses, utilizing its proprietary drug discovery platform technology. Cocrystal Pharma is working on various clinical assets, such as the oral PB2 inhibitor CC-42344 for Influenza A and the first-in-class oral norovirus/coronavirus protease inhibitor CDI-988, which has shown favorable Phase 1 results. The company is also exploring pandemic preparedness collaboration opportunities and has a seasoned leadership team with experienced management and senior scientists, including two Nobel laureates. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.